(edited out names etc)
Thank you for your interest in Clinuvel. You are correct in your understanding that CUV1647 is not being developed for cosmetic application but is targeting pharmaceutical milestones. We seek to develop CUV1647 for patients worldwide affected by their adverse reactions to UV-radiation.
Clinuvel is currently conducting or preparing to conduct clinical trials for CUV1647 in the following UV-related disorders:
· Squamous Cell Carcinoma (SCC) in organ transplant patients
SCC is a malignant tumour of the skin, the second most common form of skin caner. SCC is caused by prolonged exposure to UV-radiation.
· Actinic Keratosis (AK) in organ transplant patients
AK is a pre-cancerous skin growth usually caused by sun exposure.
· Polymorphic Light Eruption (PLE also known as PMLE)
PMLE is a severe sun-poisoning following exposure to UV-radiation.
· Erythropoietic Protoporphyria (EPP)
EPP is a rare inherited porphyrin metabolism disorder (caused by a fault in iron synthesis) that affects between one in 200,000 people. This condition, also known as absolute sun intolerance
· Solar Urticaria (SU)
SU is an acute anaphylactic reaction to sun.
Clinuvel is preparing to start further Phase II and III clinical trials in Australia, Europe and the United States and remains on target to complete these in 2009. Over the next few years and following the completion of the clinical development program, Clinuvel will be working closely with regulators to facilitate market approval of CUV1647.
Clinuvel
